{"disease":{"id":"aml-mds","name":"aml mds"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT01252485","title":"Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms - The Biology and Outcome (BiO)-Project","phase":"","overall_status":"RECRUITING","enrollment_count":50000,"lead_sponsor_name":"University of Ulm","has_results":false},{"nct_id":"NCT03050268","title":"Familial Investigations of Childhood Cancer Predisposition","phase":"","overall_status":"RECRUITING","enrollment_count":1500,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT07205523","title":"High-Altitude Hematology Observation-Stem Cell Transplantation (HALO-SCT)","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Yigeng Cao,MD,PhD","has_results":false},{"nct_id":"NCT01929408","title":"Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients","phase":"","overall_status":"COMPLETED","enrollment_count":703,"lead_sponsor_name":"Fred Hutchinson Cancer Center","has_results":true},{"nct_id":"NCT00887068","title":"Controlled Study of Post-transplant Azacitidine for Prevention of Acute Myelogenous Leukemia and Myelodysplastic Syndrome Relapse (VZ-AML-PI-0129)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":187,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":true},{"nct_id":"NCT05175508","title":"Aza With or Without ATRA in Newly Diagnosed Unfit AML or Intermediate,High or Very High Risk MDS","phase":"PHASE2, PHASE3","overall_status":"UNKNOWN","enrollment_count":180,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT02790515","title":"Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":170,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT02632708","title":"Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":153,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT03173248","title":"Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":146,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":true},{"nct_id":"NCT03647800","title":"Study of APVO436 in Patients With AML or MDS","phase":"PHASE1","overall_status":"UNKNOWN","enrollment_count":136,"lead_sponsor_name":"Aptevo Research and Development LLC","has_results":false},{"nct_id":"NCT06972641","title":"Molecular Genetics Guide the Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation","phase":"PHASE2, PHASE3","overall_status":"RECRUITING","enrollment_count":126,"lead_sponsor_name":"Ruijin Hospital","has_results":false},{"nct_id":"NCT02730299","title":"Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":125,"lead_sponsor_name":"Gamida Cell ltd","has_results":true},{"nct_id":"NCT06533761","title":"Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":125,"lead_sponsor_name":"Stelexis BioSciences","has_results":false},{"nct_id":"NCT06098313","title":"HCT With PTCy in Higher-risk MDS","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":113,"lead_sponsor_name":"Asan Medical Center","has_results":false},{"nct_id":"NCT04318678","title":"CD123-Directed T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":108,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":false},{"nct_id":"NCT04202003","title":"A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":105,"lead_sponsor_name":"TJ Biopharma Co., Ltd.","has_results":false},{"nct_id":"NCT04275518","title":"A Phase Ib Study of APG-115 Single Agent or in Combination With Azacitidine or Cytarabine in Patients With AML and MDS.","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":102,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT03613532","title":"Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":102,"lead_sponsor_name":"Jacqueline Garcia, MD","has_results":false},{"nct_id":"NCT03275636","title":"Haploidentical Donor vs mMUD in Hematological Malignancies","phase":"PHASE2, PHASE3","overall_status":"COMPLETED","enrollment_count":98,"lead_sponsor_name":"DKMS gemeinnützige GmbH","has_results":false},{"nct_id":"NCT05665530","title":"A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":86,"lead_sponsor_name":"Prelude Therapeutics","has_results":false},{"nct_id":"NCT07384715","title":"First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) or Higher-risk Myelodysplastic Syndrome (HR-MDS)","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":78,"lead_sponsor_name":"Genmab","has_results":false},{"nct_id":"NCT06717958","title":"Prospective Evaluation of Ivosidenib Maintenance Following Allogeneic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Neoplasia With IDH1 (Isocitrate Dehydrogenase 1) Mutation","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":76,"lead_sponsor_name":"Technische Universität Dresden","has_results":false},{"nct_id":"NCT00566696","title":"Mismatched Family Member Donor Transplantation for Children and Young Adults With High Risk Hematological Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":73,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":true},{"nct_id":"NCT02333058","title":"Treosulfan-based Conditioning in Paediatric Patients With Haematological Malignancies","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"medac GmbH","has_results":false},{"nct_id":"NCT02078609","title":"A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":70,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04358393","title":"A Study of APG-115 Alone or Combined With Azacitidine in Patients With AML, CMML, or MDS","phase":"PHASE1, PHASE2","overall_status":"UNKNOWN","enrollment_count":69,"lead_sponsor_name":"Ascentage Pharma Group Inc.","has_results":false},{"nct_id":"NCT03849651","title":"TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":69,"lead_sponsor_name":"St. Jude Children's Research Hospital","has_results":true},{"nct_id":"NCT07238712","title":"Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With High-risk Myeloid Malignancies and a Partially Mismatched Donor","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":60,"lead_sponsor_name":"St. Petersburg State Pavlov Medical University","has_results":false},{"nct_id":"NCT05476770","title":"Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Therapeutic Advances in Childhood Leukemia Consortium","has_results":false},{"nct_id":"NCT05884333","title":"Cord Blood Transplant in Adults With Blood Cancers","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":54,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03940352","title":"HDM201 in Combination With MBG453 or Venetoclax in Patients With Acute Myeloid Leukemia (AML) or High-risk Myelodysplastic Syndrome (MDS)","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":52,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":false},{"nct_id":"NCT04326764","title":"Panobinostat Maintenance After HSCT fo High-risk AML and MDS","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":52,"lead_sponsor_name":"Goethe University","has_results":false},{"nct_id":"NCT07347171","title":"A Phase 1 Study of CG009301 for Injection in Adult Subjects With Recurrent or Refractory Haematological Malignancies","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":45,"lead_sponsor_name":"Cullgen (Shanghai),Inc","has_results":false},{"nct_id":"NCT05285813","title":"A Phase II Study of Vibecotamab (XmAb14045) for MRD- Positive AML and MDS After Hypomethylating Agent Failure","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":42,"lead_sponsor_name":"M.D. Anderson Cancer Center","has_results":false},{"nct_id":"NCT04749355","title":"Phase 2, Open-Label, Single Arm Study, With BST-236 in Adults With R/R AML or Higher-Risk MDS","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"BioSight Ltd.","has_results":false},{"nct_id":"NCT04636918","title":"Ikervis for DED Due to GVHD Post Allo-HSCT","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":40,"lead_sponsor_name":"Singapore Eye Research Institute","has_results":false},{"nct_id":"NCT04912063","title":"Study to Evaluate Adverse Events and Movement of Lemzoparlimab in Body When Used Intravenously (IV) With Azacitidine Subcutaneously or IV and Venetoclax Orally in Participants With Acute Myeloid Leukemia and With Azacitidine With or Without Venetoclax in Participants With Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":40,"lead_sponsor_name":"AbbVie","has_results":false},{"nct_id":"NCT02979366","title":"Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":38,"lead_sponsor_name":"Institut de Recherches Internationales Servier","has_results":false},{"nct_id":"NCT05025098","title":"Precision Therapy Versus Standard Therapy in AML and MDS in Elderly","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":36,"lead_sponsor_name":"University Hospital, Akershus","has_results":false},{"nct_id":"NCT04139434","title":"Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":32,"lead_sponsor_name":"Newave Pharmaceutical Inc","has_results":false},{"nct_id":"NCT04443751","title":"A Safety and Efficacy Study of SHR-1702 Monotherapy in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":31,"lead_sponsor_name":"Jiangsu HengRui Medicine Co., Ltd.","has_results":false},{"nct_id":"NCT04644016","title":"Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":31,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT07500753","title":"A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"The First Affiliated Hospital of Soochow University","has_results":false},{"nct_id":"NCT02418000","title":"A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 and/or Ras Mutations","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":27,"lead_sponsor_name":"Spirita Oncology, LLC","has_results":true},{"nct_id":"NCT04473911","title":"Haplo Peripheral Blood Sct In GVHD Prevention","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":25,"lead_sponsor_name":"Zachariah Michael DeFilipp","has_results":false},{"nct_id":"NCT02226861","title":"Ultra-Low Dose IL-2 Therapy as GVHD Prophylaxis in Haploidentical Allogeneic Stem Cell Transplantation","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":24,"lead_sponsor_name":"National Heart, Lung, and Blood Institute (NHLBI)","has_results":false},{"nct_id":"NCT03465540","title":"Safety, Tolerability, Pharmacokinetics and Efficacy of AMG 397 in Subjects With Selected Relapsed or Refractory Hematological Malignancies","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":24,"lead_sponsor_name":"Amgen","has_results":true},{"nct_id":"NCT03787498","title":"A Study of PLX2853 in Relapsed or Refractory Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":22,"lead_sponsor_name":"Opna Bio LLC","has_results":false},{"nct_id":"NCT02626715","title":"Reduced-Intensity Conditioning (RIC) and Myeloablative Conditioning (MAC) for HSCT in AML/MDS","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Randy Windreich","has_results":true},{"nct_id":"NCT03466320","title":"DEPLETHINK - LymphoDEPLEtion and THerapeutic Immunotherapy With NKR-2","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Celyad Oncology SA","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}